Phase 1 Peripheral Arterial Disease Trial, Recruiting NCT05699005 Sponsor: University Hospital, Lille Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Phase 1 Peripheral Arterial Disease Trial, Recruiting

NCT05699005
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People currently being supported by a specific heart-lung bypass device used through the blood vessels (called peripheral VA-ECMO)
  • People who have this support in place because their heart is not pumping enough blood (a condition called cardiogenic shock)
  • People whose doctors estimate they have a life expectancy of more than 90 days
  • People who have a central venous line (a tube inserted into a large vein) in place that can be used to measure oxygen levels in the blood

Who may not be able to join:

  • People who are pregnant
  • People who do not have health insurance
  • People who object to receiving blood transfusions
  • People with a known inherited condition affecting the structure or function of their hemoglobin (the protein in red blood cells that carries oxygen)
  • People with a specific blood chemistry imbalance where the blood is too alkaline, with a pH above 7.8 (confirm with trial site)
  • People who received ECMO support during or immediately after a cardiac arrest resuscitation attempt (called eCPR) (confirm with trial site)
  • People who have been legally determined to lack the capacity to make their own decisions

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mouhamed MOUSSA, MD, University Hospital, Lille

Phone: 0320445962

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
18 September 2023
Est. completion
18 March 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Number of PRBCs transfused per VA-ECMO day of support

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov